MaxCyte Platform > Technology > Technology Scalability
High content and high throughput campaigns require a large number of cells to perform a single screen.
Large cell numbers are also needed for protein production and use in cell therapy applications. MaxCyte
electroporation has the unique scalability to transfect as few as 5 x 105 cells within seconds for assay
development and lead optimization or as many as 1 x 1010 cells in less than 30 minutes for library screening,
protein production, and cell therapy. Other transfection technologies require multiple small-scale
transfections, re-optimization of transfection protocols and/or bulk usage of costly transfection agents.
Transfection quality and cell performance in downstream applications are unaffected by transfection scale up
using MaxCyte electroporation. Additionally, migration from small to large scale transfection is seamless,
requiring no further assay optimization.
GPCR agonist responses are unchanged by scale up
There are any number of functional and biochemical assay methods for assessing GPCR activation,
receptor inhibition and signaling pathway usage. Many of these methods require cellular engineering
such as over expression of targets or artificial coupling to specific G alpha subunits. Transient
transfection, and more specifically MaxCyte STX scalable electroporation, can quickly and reproducibly
transfect large numbers of cells with minimal off target effects and proven performance in downstream
GPCR assays such as cAMP regulation and calcium flux assays.
The experiments summarized in Figure 1 were conducted to examine the effects of electroporation run size on
the performance of the transfected cells in a functional GPCR assay. HEK cells transfected using both small
and large scale MaxCyte electroporation produced comparable concentration-dependent cAMP responses to a natural
GPCR ligand. These results highlight the ability of the MaxCyte STX to produce transfected cells at the numbers
required for high throughput/high content screening and profiling of GPCR targets. Additionally, the results
illustrate the seamlessness of assay scale up as identical electroporation parameters were used an no optimization
performed for large scale transfection.
Figure 1. cAMP GPCR Assay: Small vs. Large Scale Electroporation Assay Performance. HEK 293F cells
suspended in MaxCyte electroporation buffer (1x108 cells/mL) were mixed with a GPCR expression plasmid (100 µg/mL)
and transfected using small or large scale MaxCyte electroporation. Cells were incubated with increasing
concentration of the natural ligand and GPCR activity assayed through a cAMP ELISA 18 hours post-electroporation.
MaxCyte scalable electroporation produces similar performance to stable cell lines
To demonstrate the scalability of MaxCyte electroporation, a high content PI3 kinase assay was performed on
cells transiently transfected with a plasmid expressing the PI3P binding protein eGFP-2XFYVE using small-scale
(SCEP) and large-scale electroporation (LSEP). In addition, a stable cell line expressing the identical
reporter protein was tested. No significant differences in IC
50 values following exposure to wortmannin, a
PI3 kinase inhibitor, were observed among the three cell populations (Figure 2). These results demonstrate
the capacity of the MaxCyte STX to produce functionally relevant cells via transient transfection at the
multi-billion cell scale. It also highlights the ability to decrease the reliance on stable cell lines as
MaxCyte transiently transfected cells produced comparable assay results without the time and cost commitments
of creating a stable cell line.
Figure 2: Cells were transfected with a plasmid encoding eGFP expressed as a fusion protein with tandem PI3P
binding domains (2XFYVE). Active PI3 kinase leads to localization of GFP to endosomes and visualized as
granules. PI3K inhibition leads to redistribution of fluorescence throughout the cytoplasm. Cells transiently
transfected via small or large scale electroporation or cells stably expressing eGPF-2XFYVE were incubated for
30 minutes with increasing concentrations of wortmannin. PI3K activity was assessed using high content screening
to visualize granule localization.
Similar antagonist profiles following small and large scale electroporation
Jurkat cells were co-transfected with dual reporter plasmids for a nuclear receptor (NR) assay via small and large
scale MaxCyte electroporation using identical electroporation protocols to compare assay results. Cells were
incubated with a known nuclear receptor antagonist following transfection and a luciferase reporter gene
assay performed. The signal-to-background (S/B) ratio and antagonist EC
50 values were comparable for
cells from both sets of transfected cells, illustrating the scalability and consistency of MaxCyte's
transfection process (Figure 3).
Figure 3. Scale up of a dual plasmid nuclear receptor assay. Jurkat cells were suspended in MaxCyte
electroporation buffer with 200 µg/mL of a dual plasmid mixture containing a luciferase reporter plasmid
with GAL4 binding sites and an activator plasmid encoding a GAL4 DNA binding domain-nuclear receptor
ligand binding domain fusion protein. 4x107 cells were transfected by small scale (static) electroporation
in an OC-400 processing assembly; 1.7x109 cells were transfected by large scale (flow) electroporation
in a CL-2 processing assembly. Cells were cryopreserved 30 minutes post electroporation. Cells were
thawed and immediately plated with antagonist and a luciferase reporter gene assay performed on the
following day. Error bars denote standard deviation of 3 replicate wells.